Health Archive » June, 2010

Health - June, 2010

230 articles

• Medical Process Patent Cases First Big Test For Bilski
• United American 'Greenmailing' Case Tossed
• Alcon Shareholders Seek 2nd Shot In Merger Suit
• La. Can't Recover Vioxx Payments From Merck: Judge
• USPTO Nixes Apotex Bid for Plavix Patent Re-Exam
• Sanofi Settles False Patent Marking Qui Tam Suit
• Jones Day Reps Sanofi In $560M TargeGen Buy
• Wyeth Can't Combine Texas Prempro Cases: Judge
• Proskauer, Jones Day Rep Celgene In $3B Abraxis Buy
• Clinical Trials And The Learned Intermediary Doctrine
• FDA Warns Baxter Over Dialysis Systems
• AstraZeneca Crestor Patent Found Valid, Enforceable
• Bristol-Myers Execs Escape Fraud Charges With Catch
• Bilski Prompts Remand In Medical Process Cases
• Bilski Puts Patent Examiners Back At Square One
• Reports Spur Lawmakers To Call For End To Avandia
• Thompson Hine Adds Arnold & Porter Product Pro
• Will Inequitable Conduct Finally Be Reformed?
• Mylan Barred From Selling Generic Oracea
• Judge Affirms Bar On Teva Discovery In Aricept IP Suit
• Scrushy, Ex-Gov Convictions Vacated After Skilling
• High Court Lets Nigerians' Pfizer Suits Stay In US
• Bayer To Pursue IP Row Over Teva's Gianvi In Nev.
• Abbott Goes After Mylan Over Simcor ANDA
• Genzyme Targets Sandoz Over Kidney Drug ANDA
• Bilski Serves As Justice Stevens' Swan Song
• Midland Exits Life Technologies' Assay Patent Suit
• UK Court Rules Prior Art After Priority Date Counts
• One A Day False Ad Action Survives Dismissal Bid
• SG To Weigh In On Stanford, Roche HIV Patent Case
• Leahy Says Bilski Exemplifies Patent Law Problems
• SEC Wants Asset Info From Taro Pharma Exec, Sons
• Lack Of Guidance In Bilski Will Spark Suits: Attys
• Jury Stuns Merck With $8M Verdict For Fosamax Plaintiff
• Consultants At WellCare Unit Launch OT Action
• New Star Cuts Deal In CardioFocus Laser Patent Row
• Healthy Smokers Win Class Cert. Against Philip Morris
• Amgen Shareholders Appeal ERISA Loss To 9th Circ.
• Zydus Gives Up Attempt To Market Generic Astelin
• Gilead To Pay Up To $120M For CGI Pharmaceuticals
• Merck Homes In On Defect Claims In Fosamax Closing
• Fed. Circ. Sends Hip Replacement Patent Suit To Ind.
• J&J Scores Another Win Over Fake OneTouch Strips
• 7th Circ. Upholds Remand Of Bayer Trasylol Suits
• Lawyers Not Sold On New Patent Examiner Rules
• Purdue Claims Construction Prevails In Embeda IP Suit
• The Future Of Biosimilars In Health Care And Litigation
• UK Court Finds Smith & Nephew Infringed Kinetic's IP
• Fosamax Jurors Can Consider Plaintiff's Smoking
• Ohio High Court Upholds Limits On Pregnancy Leave
• Spectranetics To Pay $8.9M To End Securities Suits
• Vanderbilt V. ICOS And Proving Joint Inventorship
• Trasylol Plaintiffs Lose Bid To Use Expert
• Respironics Apnea Patent Ruled Valid But Not Infringed
• Apotex Fends Off Patent Suit Over Pinkeye Treatment
• Schering Fails To Thwart Securities Suit Over Vytorin
• Jaw Issues Not A Reason To Stop Fosamax: Expert
• Insurers Escape Liability In Mylan Antitrust Suits
• Aventis' Allegra Patent Survives Impax Assault
• 2nd Circ. OKs $5M Deal In Telik Cancer Drug Suit
• Reed Smith Snags Neal Gerber Health, Insurance Trio
• Lenox-MacLaren, Medtronic End Bone Mill Patent Row
• Mylan Appeals Dismissal Of Prilosec Antitrust Claims
• Avoiding Pitfalls In Pharma Trademark Clearance
• Class Action From Digitek MDL Tossed
• Merck Expert Decries FDA Fosamax Report
• Judge Throws Trading Suspect's Bail Plan In Limbo
• Skadden Reps Valeant In $3.2B Biovail Merger
• FTC Settles Price-Fixing Claims With Minn. Health Co-Op
• Prempro Punitive Damages Case Back In District Court
• Smith & Nephew Wins Ban On Arthrex Surgery Device
• Philips Sues Zoll Medical Over Defibrillator Patents
• Solvay Cert Refusal Leaves FCA Circuit Split In Place
• Fair Ex Parte Communication With Doctors In MDLs
• High Court Won't Hear Procrit Whistleblower Suit
• Claims Trimmed In Cancer Insurance Coverage Action
• UBS Insider Trading Suspect Still In Custody
• AstraZeneca To Pay $103M To Settle AWP Claims
• Judge Buries Barr's Plan For Generic Argatroban
• MMA Fires Off Appeal Of TLC Vision Plan Confirmation
• MDs Take $10M Greenberg Malpractice Suit To Fed. Circ.
• Health Care Reform 101: For Hospitals
• Alcon Shareholders Can't Keep Merger Suit In US
• Walgreen, CVS Caremark Resolve Drug Plan Feud
• NC Dental Board Practices Anti-Competitive: FTC
• Fosamax Plaintiff Takes The Stand
• Judge Nixes Infosint's $15M Patent Win Over Citalopram
• 6th Circ. Reverses Sulzer Win In Implant Defect Case
• Red Cross Draws $16.2M In FDA Blood Safety Fines
• Pfizer Sues Mylan To Block Generic Sutent
• $33M Fee Award From E-Ferol Settlement Stays Intact
• Impax Asks To Appeal Budeprion MDL Dismissal Bid
• False Statement Claims V. Biovail Execs To See Trial
• Teva To Alter Ads For Generic Yaz After Bayer Outcry
• AstraZeneca Fails To Block Generic Nexium In Canada
• Depomed Yanks Diabetes Drug Glumetza
• Myriad Appeals Invalidation Of Human Gene Patents
• Health Care Reform 101: For Life Sciences Cos.
• Calif. Prescribes Extra Review For Insurer Rate Changes
• Health Care Reform 101: For Physicians
• USPTO-POPA Propose New Patent Examiner Rules
• Covidien Snaps Up Somanetics For $250M
• MedImmune Jabbed With $15M Flu Vaccine Royalty Suit
• FDA Launches Data-Sharing System For New Drugs
• Allergan Goes After Apotex Over Combigan ANDA
• Fosamax Trial Expert Stumbles Over Report Origins
• Alpin, AIM Settle I-Flow Drug Pump Patent Claims
• Abbott Loses Bid To Toss Humira Cancer Suit
• Bayer Accuses Teva Of Falsely Advertising Yaz Generic
• Pa. Hospital Takes Amgen Tying Fight To 3rd Circ.
• FTC Seeks To Allay Doctors' Antitrust Fears
• Health Care Reform 101: For Insurers
• Obama Exempts 'Grandfathered' Plans From Overhaul
• J&J Gets Pa.'s Off-Label Risperdal Suit Tossed
• Hypertension Drugs Tied To Higher Cancer Risk
• AMRI, Sanofi Win Injunction Blocking Generic Allegra
• Claims Pared In Max Planck RNA Patent License Suit
• Abbott Sales Reps Ruled Not Exempt From FLSA
• US Takes Ex-Tenet GC Medicare Spat To 11th Circ.
• FDA Warns Gene Test Makers They Need Agency OK
• Trade Secrets Claim Added To Patent Suit Over Delsym
• Genzyme Targets Anchen Over Hectorol ANDA
• Health Care Reform 101: For Employers
• ScImage Settles In Acacia Unit's Imaging Patent Suit
• House Panel Probes Wyeth Off-Label Allegations
• Supreme Court To Hear Matrixx Zicam Securities Case
• Ciba, Novartis Partly Dodge Contact Lens Injury Suit
• 7th Circ. To Review Patients' Antitrust Class Cert. Denial
• Judge Rejects Dismissal, Injunction In Aldara IP Spat
• Allcare Fights To Keep McKool In $5.5M Fees Scrap
• Schering-Plough Off-Label Marketing MDL Dunzo
• US Wants Dey's AWP Evidence Against It Tossed
• Schering Loses Bid To Split Suit Over Generic Vytorin
• I-Flow Settles Pain Pump Patent Suit Against Apex
• The Do's And Don'ts Of Gathering Info
• Applera Seeks Enzo IP Spat Stay For High Court Appeal
• DOJ Requires Divestiture For Amcor's $2B Alcan Buy
• FTC Fights Nixing Of AndroGel Reverse Payment Suit
• GSK Expands In Argentina With $253M Phoenix Buy
• Class Certified In Calif. Health Worker Wage Dispute
• Otsuka Sues Zydus To Block Generic Abilify
• Fed. Circ. Remands Stryker IP Suit, Orders New Judge
• FDA Rebukes Pfizer Over Late Reports Of Side Effects
• ITC To Review Drugs Up For Duty-Free Treatment
• Digitek Plaintiffs Want 2nd Look At Class Cert.
• Neurontin Judge Doubts Atty Can Rep 292 Plaintiffs
• Smith & Nephew Sues Rival Over Cutting Tool Patent
• Apotex Dodges Extra Damages In Prilosec Patent Suit
• Mayer Brown Reps Healthcare Solutions In $517M Sale
• Fosamax Witness Slams Merck's Bone Death Claims
• Merck, Upsher-Smith Appeal Class Cert. In K-Dur Suit
• FDA Warns Drugmaker Aveva Over Plant Problems
• NLRB Approves Medical Residents' Right To Unionize
• Cochlear Settles Kickback Claims On Hearing Implants
• All Eyes On J&J Case As FDA Tests Criminal Powers
• Blue Cross Sues Pfizer Over Off-Label Marketing
• 1-800 Contacts Sues Walgreen Over Web Ads
• Medtronic Sues Bovie Over Surgical Device Patent
• Sidley Reps Allscripts In $1.3B Deal For Eclipsys
• USPTO Issues 1st Parthenogenetic Stem Cell Patent
• Icahn Gets 2 Seats On Genzyme Board In Proxy Deal
• Pfizer, West-Ward Recall IV Drugs Over Contamination
• J&J Seeks Dismissal Of Omnicare Kickback Case
• Plaintiff In Fosamax Bellwether Says Merck Hid Risks
• Endo Resolves Opana Patent Suits V. Impax, Sandoz
• No Win Yet For Royal Sun In Stolen Kits Coverage Spat
• Settlement Halts Trial In Mentor ObTape MDL
• 3rd Circ. Tosses Pa. Beryllium Exposure Class Actions
• Fired Nurse Targets Mich. Medical Center In OT Suit
• St. Vincent Monitor Says $46M Claim Is Too High
• Wockhardt Fails To Nix Sepracor's Lunesta Patents
• Monopoly And The Big Bat Theory In Antitrust Law
• Sanofi, Abbott Fail To Halt Release Of Generic Tarka
• Tying Suit Against Amgen Over Blood Drug Tossed
• 3rd Circ. Nixes Class' Appeal Of Fen-Phen Atty Fees
• Proskauer Reps Grifols In $3.4B Talecris Buy
• Iovate Trims Claims In $13.5M Hydroxycut MDL Case
• Biotech Co.'s Suit Over Mintz Levin IP Work Trimmed
• Stryker Implant Suit Meets Preemption Test: Judge
• The Art Of Client Alerts And Bulletins
• Lawyers Gear Up For Round 2 Of Fosamax Bellwether
• Healthways Settles Medicare Securities Suit For $24M
• KV Unit Sales Rep Seeks Cert. In OT Collective Suit
• Chem Rx To Keep Biz Open With Existing Cash
• St. Jude To Pay $3.7M Over Hospital Kickback Scheme
• DOJ Asks 2nd Circ. To Rehear Bayer Pay-For-Delay Suit
• Latest Watson CEO Brief Rips Motive For FTC Subpoena
• MicroAire Loses Bid For Injunction On Arthrex Device
• The 4 Factors Behind The Cipro En Banc Hearing
• Groups Urge Fed. Circ. To Rethink Novo Nordisk Win
• Prempro Plaintiffs Try To Block Preemption Defense
• Fed. Circ. Deems Purdue's Tramadol Patents Invalid
• Wyeth Wins Brawl Over Heartworm Drug In 1st Circ.
• Sequenom VP Inflated Down Syndrome Test: SEC
• Becton Dickinson Resolves Workers' OT Suit
• Javelin Says Hospira Breached $145M Merger Deal
• ERISA Suit Over GSK's Stiefel Acquisition To Proceed
• House Panel Turns Up Heat On J&J Over Recalls
• USPTO Reaffirms Solodyn Patent
• Axiom Loses Spinal Machine Suit By Default
• Dr. Reddy's Agrees To Hold Off On Generic Allegra
• Biotechs Face Higher Bar For Induced Infringement
• Shire Sues Anchen Over Generic Intuniv
• 10th Circ. Remands Wyeth, GSK Suits Over Preemption
• Abbott's Appeal Bid Nixed In Norvir Pricing Suits
• Bayer Yaz Patents Invalid, Teva Claims
• Fed. Circ. Nixes $15.7M Award In Blood Device IP Suit
• USTR Preps More Drugs For Duty-Free Treatment
• Ortho, Amneal Settle Patent Spat Over Ultracet
• Flonase Indirect Purchasers Press For Class Status
• Teva Fails To Block Paddock's Cenestin ANDA
• Court Clears Fen-Phen Attys Of Malpractice Claims
• Biogen Sues Bayer, Others Over Multiple Sclerosis Drug
• Mega-T Maker To Pay $2.5M Over Diet Pill Claims
• FDA Warns Dexcom Over Glucose Monitor Problems
• Hospital Takes Angioplasty Antitrust Fight To 9th Circ.
• DC Circ. Revives Hospital Race Bias Class Action
• Allergan Strikes Deal In Dry Eye Treatment Patent Suit
• Gov't Workers Get Same-Sex Long-Term Health Care
• 3rd Circ. Affirms Nixing Of Kickback Suit V. Stryker
• Judge Tosses Conviction Of WebMD Unit's Ex-Execs
• Bayer Sues Teva Over Generic Yaz
• Medical Resident FICA Dispute Heads To High Court
• GSK Settles 1st Avandia Suit Slated For Trial
• Accentia Files Plan Aimed At Boosting MS Drug
• FTC Pushes For Watson CEO To Testify In Provigil Probe
• DOJ Seeks More Info On Oracle, Phase Forward Merger
• SG Urges Justices To Reject Pfizer Nigeria Case
• Novo Nordisk Hit With Antitrust Action Over Prandin
• Covidien To Pay $2.6B For Vascular Device Maker